Tivicay Pd (Dolutegravir Sodium) Patent Expiration, LOE Window & CMS Spending

Tivicay Pd (Dolutegravir Sodium) by GSK: FDA Orange Book core substance LOE 2030-06-08, 0 AB generics, $592K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN213983 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2030-06-08
Last Listed Patent or Exclusivity Date2030-06-08
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$592K
2024 Medicare Part D Spend$38K
2024 Medicaid Spend$554K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 17.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.